CBMX is also developing a chromosomal microarray analysis (CMA) for genetic prenatal diagnosis and evaluation of stillbirths. Their CMA test would replace karyotyping (a test to examine chromosomes in a sample of cells, which can help identify genetic problems as the cause of a disorder or disease). Both tests detect chromosomal disorders.
The announcement Friday of two studies published in leading journals favors CBMX’s CMA over karyotyping. Their test, a women’s health service option, could complement SQNM’s rather than competing. If SQNM is going to grow into the testing service of choice for pregnant woman, it needs a spectrum of conclusions for the expectant parents. So, CMBX and others should be considered as possible candidates for mergers.